Changes in cortical cytoskeletal and extracellular matrix gene expression in prostate cancer are related to oncogenic ERG deregulation

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Schulz, Wolfgang A ^a   Ingenwerth, Marc ^a   Djuidje, Carolle E ^a   Hader, Christiane ^a   Rahnenführer, Jörg ^b   Engers, Rainer ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; ERYTHROCYTE BAND 4.9 PROTEIN; EZRIN; GLUTATHIONE TRANSFERASE P1; PROTEIN DLG1; PROTEIN EPB41L1; PROTEIN EPB41L2; PROTEIN EPB41L3; PROTEIN EPB41L45; PROTEIN EPB41L4B; PROTEIN FBLN1; PROTEIN SPOCK1; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ACTIN; ERG PROTEIN, HUMAN; GSTP1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NEURONAL MEMBRANE CYTOSKELETAL PROTEIN 4.1; NEUROPEPTIDE; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CYTOSKELETON; DNA METHYLATION; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PROMOTER REGION; PROSTATE ADENOCARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ADENOCARCINOMA; AGED; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; ONCOGENE; PROSTATE TUMOR;

ACTINS; ADENOCARCINOMA; AGED; CYTOSKELETAL PROTEINS; CYTOSKELETON; DISEASE PROGRESSION; DNA METHYLATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEUROPEPTIDES; ONCOGENES; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS;

EID: 77956815993     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-505     Document Type: Article

References (34)

1. Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 2002, 115:3991-4000. 10.1242/jcs.00094, 12356905.
2. Calinisan V, Gravem D, Chen RPH, Brittin S, Mohandas N, Lecomte MC, Gascard P. New insights into potential functions for the protein 4.1 superfamily of proteins in kidney epithelium. Front Biosci 2006, 11:1646-66. 10.2741/1911, 16368544.
3. Parra M, Gascard P, Walensky LD, Gimm JA, Blackshaw S, Chan N, Takakuwa Y, Berger T, Lee G, Chasis JA, Snyder SH, Mohandas N, Conboy JG. Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J Biol Chem 2000, 275:3247-55. 10.1074/jbc.275.5.3247, 10652311.
4. Hanada T, Takeuchi A, Sondarva G, Chishti AH. Protein 4.1-mediated membrane targeting of human discs large in epithelial cells. J Biol Chem 2003, 278:34445-50. 10.1074/jbc.M305209200, 12807908.
5. Bernkopf DB, Williams ED. Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets 2008, 12:845-53. 10.1517/14728222.12.7.845, 18554153.
6. Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenführer J. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007, 6:14. 10.1186/1476-4598-6-14, 1797054, 17280610.
7. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D, Hynes RO. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 2007, 104:12784-9. 10.1073/pnas.0705499104, 1924789, 17640904.
8. Shimizu K, Nagamachi Y, Tani M, Kimura K, Shiroishi T, Wakana S, Yokota J. Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in high-metastatic K1735 murine melanoma cells. Genomics 2000, 65:113-20. 10.1006/geno.2000.6154, 10783258.
9. Chauhan S, Pandey R, Way JF, Sroka TC, Demetriou MC, Kunz S, Cress AE, Mount DW, Miesfeld RL. Androgen regulation of the human FERM domain encoding gene EHM2 in a cell model of steroid-induced differentiation. Biochem Biophys Res Commun 2003, 310:421-32. 10.1016/j.bbrc.2003.08.147, 2740477, 14521927.
10. Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL, Ittmann M. Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate 2006, 66:1641-52. 10.1002/pros.20474, 16927306.
11. Laprise P, Lau KM, Harris KP, Silva-Gagliardi NF, Paul SM, Beronja S, Beitel GJ, McGlade CJ, Tepass U. Yurt, Coracle, Neurexin IV and the Na(+), K(+)-ATPase form a novel group of epithelial polarity proteins. Nature 2009, 459:1141-5. 10.1038/nature08067, 19553998.
12. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 2006, 281:29938-48. 10.1074/jbc.M602237200, 16873375.
13. Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G, Pousette A, Flores-Morales A. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 2010, 29:1531-42. 10.1038/onc.2009.442, 20010876.
14. Lutchman M, Pack S, Kim AC, Azim A, Emmert-Buck M, van Huffel C, Zhuang Z, Chishti AH. Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression. Cancer Genet Cytogenet 1999, 115:65-9. 10.1016/S0165-4608(99)00081-3, 10565303.
15. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-73. 10.1038/nrc2620, 19262571.
16. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-90. 10.1016/j.cell.2009.11.007, 19945376.
17. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8:497-511. 10.1038/nrc2402, 2711688, 18563191.
18. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008, 68:3094-8. 10.1158/0008-5472.CAN-08-0198, 18451133.
19. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008, 68:8516-24. 10.1158/0008-5472.CAN-08-1147, 2597580, 18922926.
20. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009, 41:619-24. 10.1038/ng.370, 2835150, 19396168.
21. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007, 31:882-8. 10.1097/01.pas.0000213424.38503.aa, 17527075.
22. Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004, 91:985-94. 2409889, 15292941.
23. Hoffmann MJ, Müller M, Engers R, Schulz WA. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 2006, 72:1577-88. 10.1016/j.bcp.2006.06.020, 16854382.
24. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009, 56:275-86. 10.1016/j.eururo.2009.04.036, 19409690.
25. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Müller M, Schulz WA. Downregulation of several fibulin genes in prostate cancer. Prostate 2007, 67:1770-80. 10.1002/pros.20667, 17929269.
26. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P. Expression of ezrin in prostatic intraepithelial neoplasia. Urology 2004, 63:609-12. 10.1016/j.urology.2003.09.068, 15028477.
27. Valdman A, Fang X, Pang ST, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol 2005, 48:852-7. 10.1016/j.eururo.2005.03.013, 16230228.
28. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998, 7:531-6.
29. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64:1975-86. 10.1158/0008-5472.CAN-03-3972, 15026333.
30. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41:524-6. 10.1038/ng.371, 2898503, 19396167.
31. Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD, McDonnell DP. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 2009, 36:405-16. 10.1016/j.molcel.2009.10.020, 19917249.
32. Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 1997, 157:673-6. 10.1016/S0022-5347(01)65248-0, 8996396.
33. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006, 10:100-25. 10.1111/j.1582-4934.2006.tb00293.x, 16563224.
34. Tan JS, Mohandas N, Conboy JG. Evolutionarily conserved coupling of transcription and alternative splicing in the EPB41 (protein 4.1R) and EPB41L3 (protein 4.1B) genes. Genomics 2005, 86:701-7. 10.1016/j.ygeno.2005.08.005, 16242908.